Research on Acute Promyelocytic Leukemia in Asia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to gather collaborative data on the epidemiology, clinicopathologic features, and treatment outcomes of newly diagnosed and relapsed Acute Promyelocytic Leukemia (APL) in Asia. It will compare the efficacy of oral arsenic trioxide (oral-As2O3) with intravenous arsenic trioxide (i.v.-As2O3) in treating APL, leveraging both retrospective and prospective data from various Asian countries. The study seeks to establish the long-term benefits of oral-As2O3, which has shown promising results in Hong Kong, and to facilitate its broader application across Asia.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Patients aged 18 or above
* Acute promyelocytic leukaemia with PML/RARA
* Acute myeloid leukaemia with variant RARA translocation

Exclusion criteria:

-Acute myeloid leukaemia without PML/RARA or variant RARA translocation

Where it's running

• Department of Medicine, the University of Hong Kong, Queen Mary Hospital
  Hong Kong, Hong Kong Recruiting

Study contacts

• Principal investigator: Harinder Gill, MD — The University of Hong Kong
• Study coordinator: Harinder Singh Harry Gill, MD
• Email: gillhsh@hku.hk
• Phone: +852 22554542

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• QTX-2101 (oral arsenic) plus ATRA for adults with low- or intermediate-risk APL

  This Phase 3 trial tests whether an oral arsenic capsule (QTX-2101) combined with ATRA works well and is safe for adults aged 18–70 with newly diagnosed low- or intermediate-risk acute promyelocytic leukemia.

  Recruiting at 36 sites Phase 3 Quetzal Therapeutics · Birmingham, Alabama and 35 other locations · NCT07504458

• Treatment for Children and Adolescents with Acute Promyelocytic Leukemia

  This study is testing a new treatment for children and teenagers with acute promyelocytic leukemia that uses a combination of medications instead of traditional chemotherapy to see if it works better and is safer.

  Recruiting at 12 sites Phase 2 Associazione Italiana Ematologia Oncologia Pediatrica · Brussels and 30 other locations · NCT04793919

• Histotripsy treatment for pancreatic cancer

  This study tests histotripsy, a non-thermal ultrasound method, to see if it can safely target and liquefy pancreatic tumors in adults with unresectable disease.

  Recruiting The University of Hong Kong · Hong Kong · NCT07873606

• Personalized 3D-printed liver models to pick adjuvant therapy after liver cancer surgery

  Doctors test whether a patient’s own 3D-bioprinted liver model can help choose the best additional treatment to lower the chance of cancer coming back after liver surgery.

  Recruiting The University of Hong Kong · Hong Kong · NCT07839767

• Need-based cancer survivorship program implementation

  This project tests a need-based survivorship program for adults who have finished cancer treatment to see if targeted screenings and referrals can help manage symptoms and weight concerns.

  Recruiting at 5 sites The University of Hong Kong · Hong Kong, Hong Kong and 4 other locations · NCT07830368

• Optimizing when weekly chatbot reminders go out to people using a chatbot for quitting smoking

  This study tests whether sending weekly reminders at different times helps people stay engaged with a chatbot smoking-cessation service.

  Recruiting The University of Hong Kong · Hong Kong · NCT07826884

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.